A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor

Phase 1

Recruiting

• Conditions: Advanced Solid Tumors; Refractory Lymphoma; Relapsed Hematologic Malignancy
• Interventions: Drug: HDM2005

• Registration Number: NCT06615193
• Lead Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Brief Summary

This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug HDM2005 in patients with relapsed/refractory B-cell lymphoma and advanced solid tumors.

Detailed Description

Not available

Study Timeline

• Study Start: 2024-08-12
• Status Verified: 2024-09
• Study First Submitted: 2024-09-19
• Study First Submitted QC: 2024-09-23
• Last Update Submitted: 2024-09-23
• Study First Posted: 2024-09-26
• Last Update Posted: 2024-09-26
• Primary Completion: 2026-06-24
• Study Completion: 2028-02-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 111

Inclusion Criteria

1. Agree to follow the study treatment protocol and visit schedule, enroll voluntarily and sign a written informed consent;
2. Male or female aged ≥ 18 years at the time of signing the ICF;
3. B-cell lymphoma: ECOG performance status of 0-2;
4. Advanced solid tumors: ECOG performance status of 0-1;
5. Life expectancy of at least 3 months;
6. Dose escalation phase: Histopathologically confirmed relapsed/refractory B-cell lymphoma following at least 2 prior lines of systemic therapy;
7. Dose expansion phase: relapsed/refractory B-cell lymphoma and advanced or metastatic solid tumor of specified type.
8. All subjects are required to provide archived tissue (5 unstained sections) obtained within the previous 2 years or fresh tissue for ROR1 expression testing at the central laboratory; in addition, relapsed/refractory lymphoma subjects are required to provide tissue sections used for previous pathological diagnosis for pathological consultation at the central laboratory;
9. Relapsed/refractory B-cell lymphoma: Subjects in Phase Ia dose escalation phase should have evaluable lesions; subjects in Phase Ib dose expansion phase should have at least 1 radiographically measurable lymph node or extranodal malignant tumor lesion (intranodal lesion defined as having a long diameter > 1.5 cm; extranodal lesion having a long diameter > 1.0 cm) as assessed by computed tomography (CT)/magnetic resonance imaging (MRI) according to 2014 Lugano criteria, and a lesion that has previously received radiotherapy is considered measurable when it shows unequivocal progression after completion of radiotherapy;
10. Advanced solid tumors: subjects are required to have at least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 ;
11. Subjects must have recovered (to ≤ Grade 1) from any AE associated with prior anticancer therapy;
12. Subjects have adequate organ and bone marrow function;
13. Female subjects of childbearing potential should agree to use contraception methods (e.g., intrauterine device, contraceptive pill, or condom) during the study and for 6 months after the end of the study; have a negative serum pregnancy test within 7 days before study enrollment; and male subjects should agree to use contraceptive avoidance measures during the study and for 6 months after the end of the study.

Exclusion Criteria

1. B-cell lymphoma: known central nervous system (CNS) involvement .
2. Advanced solid tumors: Patients with active brain metastases (defined as stable for < 4 weeks, or symptomatic, or requiring antiepileptic drug/hormonal therapy, or meningeal metastases);
3. Subjects with prior allogeneic HSCT who have developed acute graft-versus-host disease (GVHD) or persistent evidence of chronic GVHD (as manifested by ≥ Grade 2 serum bilirubin, ≥ Grade 3 skin involvement, or ≥ Grade 3 diarrhea or receiving systemic immunosuppressive therapy/prophylaxis for GVHD);
4. Subjects have another primary malignancy ,with the following exceptions: adequately treated non-melanoma skin cancer without evidence of disease recurrence and adequately treated carcinoma in situ without evidence of disease recurrence,et al;
5. History of severe bleeding disorders ;
6. History of chronic pancreatitis or acute pancreatitis within 6 months;
7. History of interstitial lung disease, radiation pneumonitis requiring steroid therapy, or any evidence of clinically active interstitial lung disease;
8. Patients with uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage after intubation and drainage, VEGF inhibitors, platinum and other drugs injection (subjects with stable symptoms for at least one week after treatment can be enrolled);
9. Prior solid organ transplantation;
10. Persistent peripheral neuropathy > Grade 1 at baseline;
11. Clinically significant cardiovascular or cerebrovascular diseases;
12. Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection requiring systemic therapy (except for localized skin or nail bed fungal infection) at enrollment;
13. Active infectious disease, such as HIV infection, active hepatitis B, active hepatitis C (positive RNA result), active syphilis;
14. Receiving corticosteroids (prednisone equivalent more than 30 mg/day);
15. Contraindication to any component of HDM2005;
16. History of drug anaphylactic shock, severe food allergy, uncontrolled asthma/COPD;
17. Female subjects who are pregnant, lactating or planning to become pregnant during the study;
18. Known history of mental illness or substance abuse that would impair the subject's ability to cooperate with study requirements;
19. Prior or current evidence of any disease, treatment, or laboratory abnormality that, in the opinion of the investigator, could affect the outcome of the study, prevent the subject from participating in the study entirely, or is not in the subjects' best interest.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
HDM2005	HDM2005	In dose escalation phase, participants will be administered escalating doses of HDM2005 at 0.3\~2.75mg/kg IV on Day 1 of repeated 21-day cycles. In dose expansion phase, participants will be administered to recommended dose for expansion (RDE) of HDM2005 on Day 1 of repeated 21-day cycles .

Primary Outcome Measures

Name	Time	Method
Incidence of dose limiting toxicity (DLT) events (for dose escalation phase)	up to 21 days following first dose	DLT will be determined by definition during the DLT observation period.
Incident and severity of adverse events(for dose escalation phase)	Until 28 days after the last dose or initiation of a new antineoplastic therapy, whichever occurs first	The safety profile of HDM2005 will be assessed by monitoring the adverse events (AE) per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0.
Objective Response Rate (ORR)(for dose expansion phase)	Until withdrawal of consent, loss to follow-up, initiation of other new antineoplastic therapy, end of study, or study termination by the sponsor, whichever occurs first (up to approximately 3.5 years)	Objective response rate (ORR), which includes best response of complete response (CR) or partial response (PR) as assessed by the investigator.
Recommended Phase 2 Dose (RP2D) (for dose expansion phase)	Approximately 3.5 years	The selection of RP2D will be based on consideration of overall safety information together with available pharmacokinetic,E-R relationships, and efficacy data.

Secondary Outcome Measures

Name	Time	Method
Plasma concentration of HDM2005, total antibody and the free MMAE	up to 28 days following last dose	Plasma concentration of HDM2005, total antibody and the free MMAE will be reported for each arm.
Immunogenicity	up to 28 days following last dose	Number and percentage of anti-drug antibody (ADA)-positive patients will be assessed.
Incident and severity of adverse events(for dose expansion phase)	Until 28 days after the last dose or initiation of a new antineoplastic therapy, whichever occurs first	The safety profile of HDM2005 will be assessed by monitoring the adverse events (AE) per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0.
Objective Response Rate (ORR)(for dose escalation phase)	Approximately 3.5 years	Objective response rate (ORR), which includes best response of complete response (CR) or partial response (PR) as assessed by the investigator.
Time to Response (TTR)	Approximately 3.5 years	TTR is defined as the interval from the start of study therapy to the first documentation of an objective response.
Progression free survival (PFS)	Approximately 3.5 years	PFS is defined as the interval from the start of study therapy to the earlier of the first documentation of disease progression/relapse or death from any cause.
Duration of Response (DOR)	Approximately 3.5 years	DOR is defined as the interval from the first documentation of objective response to the earlier of the first documentation of disease progression/relapse or death from any cause.
Overall survival (OS)	Approximately 3.5 years	OS is defined as the interval from the start of study therapy to death from any cause.

Trial Locations

Locations (8)

Henan Cancer Hospital; 🇨🇳 Zhengzhou, Henan, China

The First Affiliated Hospital of Soochow University; 🇨🇳 Suzhou, Jiangsu, China

The First Affiliated Hospital Of Nanchang University; 🇨🇳 Nanchang, Jiangxi, China

The Second Affiliated Hospital of Soochow University; 🇨🇳 Suzhou, Jiangsu, China

The Affiliated Hospital of Xuzhou Medical University; 🇨🇳 Xuzhou, Jiangsu, China

Shandong Cancer Hospital; 🇨🇳 Jinan, Shandong, China

The First Affiliated Hospital of Zhejiang University School of Medicine; 🇨🇳 Hangzhou, Zhejiang, China

The Institute of Hematology and Blood Diseases Hospital at the Chinese Academy of Medical Sciences; 🇨🇳 Tianjing, China